Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Cologne
Because fluoroquinolones have broad antimicrobial coverage, bactericidal activity, high tissue concentrations, oral bioavailability and adequate tolerability and safety profiles, they are ideal candidates as antibacterial prophylaxis in cancer patients. Randomized trials investigating the effect of an antibiotic prophylaxis on patients with intermediate neutropenia have recently been conducted with levofloxacin. The influence of moxifloxacin on the incidence of bacteremia in patients undergoing autologous hematopoetic stem cell transplantation has not been investigated. Moxifloxacin may be another promising alternative, covering a broader spectrum of gram-positive and anaerobic bacteria than first- or secondary generation fluoroquinolones and for instance it is an agent administered only once daily, thus optimizing compliance, a crucial issue in prophylaxis.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
High-dose chemotherapy followed by peripheral autologous stem cell transplantation
Underlying disease: Hodgkin Disease, non-Hodgkin-lymphoma, multiple myeloma or solid tumor
You may not be if
Allogenic stem cell transplantation
Aplastic anemia
Antibiotic treatment within seven days prior to randomization